Ensysce Biosciences to present clinical data at PAINWeek

Ensysce Biosciences is presenting clinical data at PAINWeek, the leading US pain conference, today, September 7, 2023, in Las Vegas, NV. America remains gripped by the opioid epidemic and this is creating another looming crisis: patients deprived of access to medication for severe pain. Ensysce is working to address both crises by developing unique and safer opioid products. Today the Company is presenting their groundbreaking approaches at PAINWeek 2023. This scientific session will explore the latest information on severe pain treatment, the ongoing issues with current products on the market, and examine the safety and effectiveness of two ‘Next-Generation analgesics’ from Ensysce Biosciences, PF614 and PF614-MPAR. The faculty is comprised of world experts in the field, featuring Dr. Jeff Gudin, a Pain Physician at the University of Miami. The data being presented builds a picture of unique safety combined with powerful pain relief, charting the progress of these drugs in development from animal models to compelling human clinical data. The latest data being presented will highlight the Ensysce approach to reduce prescription drug overdoses, an approach that could herald a first for the industry.